Glp 1 And Gip Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists represent a breakthrough therapeutic approach for neurodegenerative diseases. Originally developed for type 2 diabetes, these incretin hormones have shown remarkable neuroprotective properties in preclinical and clinical studies. Dual GLP-1/GIP agonists (tirzepatide) and triple agonists are now being investigated for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [1]
GLP-1 and GIP agonists work through multiple neuroprotective pathways: [2]
| Pathway | Description | [3]
|---------|-------------| [4]
| Insulin Signaling | Improve brain insulin sensitivity and glucose metabolism | [5]
| Neuroinflammation | Reduce microglial activation and pro-inflammatory cytokines | [6]
| Synaptic Plasticity | Enhance LTP, improve dendritic spine density | [7]
| Neurogenesis | Promote hippocampal neurogenesis in adult brain |
| Mitochondrial Function | Improve mitochondrial biogenesis and reduce oxidative stress |
| Protein Clearance | Enhance autophagy and reduce protein aggregate accumulation |
| Anti-apoptotic | Activate PI3K/Akt pathway to prevent neuronal death |
| Trial | Drug | Phase | Status | Indication |
|---|---|---|---|---|
| NCT04777396 | Semaglutide | III | Recruiting | Alzheimer's disease (EVOKE) |
| NCT04777409 | Semaglutide | III | Recruiting | Alzheimer's disease (EVOKE+) |
| NCT04269642 | Liraglutide | II | Completed | Alzheimer's disease (ELAD) |
| NCT02953665 | Exenatide | II | Completed | Parkinson's disease |
| NCT04236661 | Liraglutide | II | Recruiting | Parkinson's disease |
| NCT05664581 | Tirzpatide | II | Recruiting | Alzheimer's disease |
| Drug | Receptor Target | Half-life | Administration | Clinical Status |
|---|---|---|---|---|
| Exenatide | GLP-1 | 2.4h | Twice daily | Approved (T2D); PD Phase II |
| Liraglutide | GLP-1 | 13h | Daily injection | Approved (T2D); AD Phase II |
| Semaglutide | GLP-1 | 165h | Weekly injection | Approved (T2D); AD Phase III |
| Dulaglutide | GLP-1 | 93h | Weekly injection | Approved (T2D) |
| Tirzepatide | GLP-1 + GIP | 116h | Weekly injection | Approved (T2D); AD Phase II |
| Oral Semaglutide | GLP-1 | 24h | Daily oral | Approved (T2D) |
Current research focuses on:
The study of Glp 1 And Gip Agonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Athauda D, et al. Exenatide once weekly versus placebo in Parkinson's disease. 2017. ↩︎
Femminella GD, et al. GLP-1 receptor agonists in Alzheimer's disease. 2021. ↩︎
Salameh JI, et al. Tirzepatide neuroprotection in models of Alzheimer's disease. 2023. ↩︎
Gejl M, et al. Liraglutide improves cognition in Alzheimer's disease. 2022. ↩︎
Malhotra G, et al. GLP-1 agonists as disease-modifying therapy for Parkinson's. 2020. ↩︎
Li Y, et al. Incretin-based therapies and Alzheimer's disease. 2021. ↩︎
Park JS, et al. GIP receptor agonism enhances GLP-1 neuroprotection. 2022. ↩︎